JP2005314368A - 金イオン含有がん予防・治療用液剤 - Google Patents
金イオン含有がん予防・治療用液剤 Download PDFInfo
- Publication number
- JP2005314368A JP2005314368A JP2005067639A JP2005067639A JP2005314368A JP 2005314368 A JP2005314368 A JP 2005314368A JP 2005067639 A JP2005067639 A JP 2005067639A JP 2005067639 A JP2005067639 A JP 2005067639A JP 2005314368 A JP2005314368 A JP 2005314368A
- Authority
- JP
- Japan
- Prior art keywords
- gold
- liquid medicine
- cancer
- ppm
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000010931 gold Substances 0.000 title claims abstract description 75
- 229910052737 gold Inorganic materials 0.000 title claims abstract description 75
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 59
- 201000011510 cancer Diseases 0.000 title claims abstract description 39
- 239000007788 liquid Substances 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title abstract description 14
- -1 gold ion Chemical class 0.000 claims abstract description 55
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 238000011580 nude mouse model Methods 0.000 abstract description 14
- 241000699670 Mus sp. Species 0.000 abstract description 10
- 241000699660 Mus musculus Species 0.000 abstract description 8
- 239000002537 cosmetic Substances 0.000 abstract description 8
- 230000001093 anti-cancer Effects 0.000 abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 6
- 238000002054 transplantation Methods 0.000 abstract description 6
- 239000003651 drinking water Substances 0.000 abstract description 2
- 235000020188 drinking water Nutrition 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 13
- 206010006187 Breast cancer Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- QZPSXPBJTPJTSZ-UHFFFAOYSA-N aqua regia Chemical compound Cl.O[N+]([O-])=O QZPSXPBJTPJTSZ-UHFFFAOYSA-N 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 239000003973 paint Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 241000282465 Canis Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 150000003841 chloride salts Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910001902 chlorine oxide Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- KFZAUHNPPZCSCR-UHFFFAOYSA-N iron zinc Chemical compound [Fe].[Zn] KFZAUHNPPZCSCR-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【解決手段】 癌細胞を皮下移植したヌードマウスに対して金イオン含有液剤を投与したところ、腫瘍体積が非投与群に比べて有意に小さくなり、本液剤に抗腫瘍活性が認められた。また、本液剤の抗腫瘍効果は、金イオン濃度が高いほど強く認められた。したがって、金イオンを含有する本発明のがん予防・治療用液剤および抗がん剤は、抗がん作用を有する製品として、医薬品および飲食品(特に健康飲料水)、さらには化粧品等への利用が可能である。
【選択図】図2
Description
本発明のがん予防・治療用液剤は、特開2003−104898号公報に記載の方法によって製造可能である。具体的には、まず金(金箔など)を王水(塩酸3:硝酸1)で溶解した金溶液と、亜鉛および鉄を塩酸で溶解した亜鉛−鉄溶液とを混合し、この混合溶液を坩堝や蒸発皿などの耐高熱容器に入れた状態で、耐高熱容器を加熱して、混合溶液を耐高熱容器内で蒸発乾固する。
本実施例においては、癌細胞を皮下移植した実験動物に対して本発明の金イオン含有液剤を自由飲水させ、所定期間経過後に腫瘍体積を測定し、対照動物と比較することによって、本発明の金イオン含有液剤の抗腫瘍活性を評価した。
onal Journal of Oncology (2003), 23, 1671-1677頁参照)。この細胞株はヌードマウス
に移植することにより、癌転移実験のモデルとして用いられている。
本実施例においては、5種類の腫瘍細胞を使用して、本発明の金イオン含有液剤の抗腫瘍活性を評価した。使用した5種類の腫瘍細胞は、ヒト乳癌細胞株3種類(MDA−MB,MCF−7,OCUB−F)と、イヌ乳腺腫瘍細胞株2種類(CF,MCM)である。
Claims (4)
- 金イオンを有効成分として含有する、がんの予防又は治療用液剤。
- 金イオンを1ppm以上含有する、請求項1記載のがんの予防又は治療用液剤。
- 水溶液である、請求項1又は2記載のがんの予防又は治療用液剤。
- 金イオンを有効成分として含有する、抗がん剤。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005067639A JP2005314368A (ja) | 2004-03-31 | 2005-03-10 | 金イオン含有がん予防・治療用液剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004107083 | 2004-03-31 | ||
| JP2005067639A JP2005314368A (ja) | 2004-03-31 | 2005-03-10 | 金イオン含有がん予防・治療用液剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2005314368A true JP2005314368A (ja) | 2005-11-10 |
Family
ID=35442154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005067639A Pending JP2005314368A (ja) | 2004-03-31 | 2005-03-10 | 金イオン含有がん予防・治療用液剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2005314368A (ja) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11262377A (ja) * | 1996-09-11 | 1999-09-28 | Japan Ace:Kk | 純金イオン清涼飲料水 |
| WO2002068342A1 (en) * | 2001-02-27 | 2002-09-06 | Phild Co., Ltd. | Method and device for manufacturing advanced water containing ultra-fine gold particles |
| JP2003104898A (ja) * | 2001-07-26 | 2003-04-09 | Yoshio Murai | 金イオン含有液剤およびその製造方法 |
-
2005
- 2005-03-10 JP JP2005067639A patent/JP2005314368A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11262377A (ja) * | 1996-09-11 | 1999-09-28 | Japan Ace:Kk | 純金イオン清涼飲料水 |
| WO2002068342A1 (en) * | 2001-02-27 | 2002-09-06 | Phild Co., Ltd. | Method and device for manufacturing advanced water containing ultra-fine gold particles |
| JP2003104898A (ja) * | 2001-07-26 | 2003-04-09 | Yoshio Murai | 金イオン含有液剤およびその製造方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Akhtar et al. | Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers | |
| Xu et al. | Hollow calcium/copper bimetallic amplifier for cuproptosis/paraptosis/apoptosis cancer therapy via cascade reinforcement of endoplasmic reticulum stress and mitochondrial dysfunction | |
| Tian et al. | An intelligent cupreous nanoplatform with self-supplied H2O2 and Cu2+/Cu+ conversion to boost cuproptosis and chemodynamic combined therapy | |
| Huber et al. | Nicotinamide: an update and review of safety & differences from niacin | |
| US10463690B2 (en) | Method and compositions for treating cancerous tumors | |
| KR20180004202A (ko) | 여드름을 예방 및 치료하기 위한 타우린 및 마그네슘을 포함하는 국소 및 경구 제제 | |
| CN1492758A (zh) | 抗肿瘤和抗转移作用的方法和制剂 | |
| AU2016259438A1 (en) | Mitigation of animal and plant diseases using bioavailable minerals | |
| US20070218126A1 (en) | Compositions and Methods for Reducing Inflammation and Pain Associated with Acidosis | |
| HK1049962A1 (zh) | 用於缓解肿瘤和抑制癌症的方法和制剂 | |
| JP2005314368A (ja) | 金イオン含有がん予防・治療用液剤 | |
| JP2003510363A (ja) | 医薬組成物及びその使用法 | |
| Choudhary et al. | Chronopharmacokinetics | |
| EP2694056B1 (en) | Therapeutic treatment | |
| EP4335442A1 (en) | Use of adenosine diphosphate ribose as adjuvant therapy for radiation and/or anticancer therapy | |
| Hong et al. | Efficient on-demand cuproptosis induction against triple-negative breast cancer via dual-responsive black phosphorus nanosheet | |
| PL225149B1 (pl) | Rozpuszczalne w wodzie, stabilne kompleksy złota (III), sposób otrzymywania rozpuszczalnych w wodzie, stabilnych kompleksów złota (III) i ich zastosowanie | |
| JP2007508331A (ja) | オキソプラチン、その塩および誘導体を含む医薬組成物 | |
| US12357669B1 (en) | Modification of natural compounds to create products with enhanced health benefits | |
| US20220226371A1 (en) | Synthetic Cellular Membrane Chemical Ionophore Delivery System Comprising Hexa-Aqua Ligand Compositions | |
| Wang et al. | A cardiac-targeted nanozyme ameliorates myocardial infarction via antioxidation and regulation of MAPK signaling pathway | |
| PL235135B1 (pl) | Rozpuszczalne w wodzie kompleksy złota (III), sposób wytwarzania rozpuszczalnych w wodzie kompleksów złota (III) i ich zastosowanie | |
| AU2022291691A1 (en) | Synthetic cellular membrane chemical ionophore delivery system comprising hexa-aqua ligand compositions | |
| WO2011119126A1 (ru) | Применение щавелевой кислоты в производстве лечебного препарата противоопухолевого действия по отношению к злокачественным клеткам, лечебный препарат на его основе и способ лечения | |
| PL232677B1 (pl) | Wodorozpuszczalne, inteligentne kompleksy złota (III) i zastosowanie wodorozpuszczalnych, inteligentnych kompleksów złota (III) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080125 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20080307 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080321 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080307 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110607 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111108 |